VMD introduces market-monitoring system to tighten oversight of veterinary packaging

UK – The UK’s Veterinary Medicines Directorate (VMD) is preparing to roll out a new packaging “surveillance” scheme that will significantly reshape oversight of veterinary pharmaceutical packaging.

Effective February 2, 2026, the program introduces a structured market-monitoring system aimed at ensuring packaging consistency, improving compliance, and reducing unnecessary regulatory burdens for the animal health industry.

The VMD, the national authority overseeing veterinary medicines and medicated animal feed, says the scheme will introduce a more intelligence-led approach to packaging assessment.

Instead of relying on pre-submission checks and routine mock-ups, the regulator will perform targeted market sampling.

Every three months, VMD officials will select a group of products from wholesalers for analysis. All components, labels, cartons, leaflets, blister packs, bottles and printed information, will be reviewed against approved text and principles outlined in the Product Literature Standards.

Where deficiencies are identified, actions will be directed to the Market Authorization Holder (MAH).

According to the VMD, responses will be proportionate: minor issues may simply require packaging updates at the next regulatory opportunity, while more significant deviations could trigger the need for a formal variation to correct mock-ups.

In the most severe cases, findings may be escalated and tracked as product defects. Implementation timelines will depend on the severity of the non-compliance.

Updated requirements for packaging design assessments

Alongside the new surveillance process, the VMD is adjusting its requirements for packaging mock-up submissions.

From February 2, mock-ups will no longer be needed for G.I.18 Variations Requiring Assessment or during new marketing authorization procedures.

The shift is intended to free companies from routine administrative steps, reduce costs, and shorten the time to market for veterinary medicines.

It will also give the regulator flexibility to focus more closely on products where design clarity or readability may pose a risk to animal or consumer safety.

The move aligns with broader trends in pharmaceutical and healthcare packaging regulation. In 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) expanded its post-market surveillance activities for human medicines, citing the need for stronger oversight of labelling accuracy and counterfeit risks.

Similarly, the European Medicines Agency (EMA) has been strengthening readability and safety requirements for multilingual packaging and tightening controls around environmental compliance for veterinary products.

Industry observers expect the VMD’s new scheme to encourage greater consistency across veterinary packaging, particularly at a time when supply chain complexity and parallel distribution continue to challenge regulators across Europe.

For manufacturers and MAHs, the focus now shifts to ensuring processes are responsive enough to handle post-market packaging corrections while maintaining production efficiency.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE